Barrett & Company’s Eli Lilly LLY Stock Holding History

Barrett & Company’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$478K	Buy	520 +4	+0.8%	+$4.05K	0.16%	85
2025 Q4	$555K	Sell	516 -6	-1%	-$5.74K	0.19%	81
2025 Q3	$398K	Sell	522 -221	-30%	-$164K	0.14%	93
2025 Q2	$579K	Buy	743 +3	+0.4%	+$2.33K	0.22%	74
2025 Q1	$611K	Buy	740 +1	+0.1%	+$832	0.26%	68
2024 Q4	$571K	Buy	739 +3	+0.4%	+$2.48K	0.24%	71
2024 Q3	$652K	Sell	736 -316	-30%	-$284K	0.28%	64
2024 Q2	$953K	Buy	1,052 +1	+0.1%	+$800	0.43%	43
2024 Q1	$818K	Buy	1,051 +267	+34%	+$190K	0.39%	49
2023 Q4	$457K	Sell	784 -338	-30%	-$197K	0.25%	79
2023 Q3	$602K	Buy	1,122 +9	+0.8%	+$4.64K	0.35%	58
2023 Q2	$522K	Buy	1,113 +2	+0.2%	+$839	0.3%	66
2023 Q1	$381K	Buy	1,111 +4	+0.4%	+$1.35K	0.24%	82
2022 Q4	$405K	Hold	1,107	–	–	0.27%	76
2022 Q3	$405K	Buy	+1,107	New	+$351K	0.27%	76

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Barrett & Company's LLY Position: Q1 2026 in Review

Barrett & Company increased its Eli Lilly (LLY) stake by 0.78% in Q1 2026, buying an estimated $4.05K and bringing the position to 520 shares worth $478K. The position accounts for 0.16% of the portfolio, ranked #85.

Barrett & Company first reported a position in LLY in Q3 2022 and has held it in 15 quarters since. The position peaked at $953K in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Barrett & Company held 520 shares of Eli Lilly worth $478K as of Q1 2026.
Barrett & Company bought 4 Eli Lilly shares in Q1 2026, an estimated $4.05K.
Eli Lilly made up 0.16% of Barrett & Company's portfolio in Q1 2026, its #85 holding.
Barrett & Company first reported a position in Eli Lilly in Q3 2022 and has held it in 15 quarters since.
Barrett & Company's Eli Lilly position peaked at $953K in Q2 2024.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.